News
Market news, ranked by coverage
Headlines from major outlets, ranked by how widely each story is covered.
Headlines mentioning RVMD · Clear
Latest · updated 08:50 ET
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
TechnologyHealthcareIPOs & M&A Nasdaq · 14h ago
NVDA NvidiaRVMD Revolution Medicines
Revolution Medicines to Participate in November 2026 Investor Conferences
Healthcare GlobeNewswire · 16h ago
RVMD Revolution Medicines
What 3 multibillion dollar biotechs still have to prove
Healthcare Pharma Voice · Oct 27
RVMD Revolution Medicines
Cantargia Appoints Dr. Monic Stuart as Chief Medical Officer
Healthcare ACCESS Newswire · Oct 26
RVMD Revolution Medicines
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Healthcare The Wall Street Journal · Oct 25
AMGN AmgenRVMD Revolution Medicines
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape
Healthcare Clinical Trials Arena · Oct 25
RVMD Revolution Medicines
Revolution Medicines (RVMD) Stock Looks Above Fair Value Today
Healthcare Simply Wall St. · Oct 24
RVMD Revolution Medicines
Revolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks Undervalued
Healthcare Simply Wall St. · Oct 24
RVMD Revolution Medicines
Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.
Healthcare Barrons.com · Oct 23
BNTX BioNTech SEMRK Merck &
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Healthcare Benzinga · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
Healthcare TIKR · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Tango Therapeutics stock falls despite positive cancer trial data
Healthcare Investing.com · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Healthcare GlobeNewswire · Oct 23
RVMD Revolution Medicines
Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial
Healthcare MT Newswires · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Healthcare Investor's Business Daily · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
HealthcareEarnings GlobeNewswire · Oct 23
RVMD Revolution MedicinesTNGX Tango Therapeutics
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
HealthcareEarnings GlobeNewswire · Oct 21
RVMD Revolution Medicines
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
Healthcare Barrons.com · Oct 21
JNJ Johnson & JohnsonLLY Lilly
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
HealthcareAnalyst Moves Business Wire · Oct 21
PVLARCUS Arcus Biosciences
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Healthcare Benzinga · Oct 20
RVMD Revolution Medicines
Revolution Medicines (RVMD) Has an Approved Cancer Drug. Can Its $38 Billion Valuation Deliver?
Healthcare Insider Monkey · Oct 20
RVMD Revolution Medicines
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?
Healthcare Insider Monkey · Oct 20
RVMD Revolution MedicinesTNGX Tango Therapeutics
Revolution Medicines Starts Treating Patients in Phase 3 Trial for Zoldonrasib
Healthcare MT Newswires · Oct 20
RVMD Revolution Medicines
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Healthcare GlobeNewswire · Oct 20
RVMD Revolution Medicines
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
Real EstateHealthcare BioPharma Dive · Oct 19
ADC Agree RealtyMANE
Revolution Medicines Stock In Focus After EU Drug Backing
Healthcare Simply Wall St. · Oct 17
RVMD Revolution Medicines
Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
HealthcareEarnings Investing.com · Oct 16
ALNYJEF Jefferies
VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes
Healthcare Stocktwits · Oct 15
RVMD Revolution MedicinesVSTM
Revolution Medicines' Pancreatic Cancer Drug Gets EU Panel Recommendation
Healthcare MT Newswires · Oct 15
RVMD Revolution Medicines
Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Healthcare GlobeNewswire · Oct 15
RVMD Revolution Medicines
Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
Healthcare Barrons.com · Oct 14
MRK Merck &MRNA Moderna
Revolution Medicines Seeing Enthusiasm for Rasonque Launch, RBC Says
IndustrialsHealthcare MT Newswires · Oct 14
RBC RBC BearingsRVMD Revolution Medicines
How headlines are chosen
Headlines link to their publishers. Stock-market stories only. Top News ranks stories by how widely they are covered (near-duplicate headlines are grouped), recency and whether they involve major companies. Sectors come from the GICS sector of the companies a story names (a story can have more than one); stories that name no company are tagged from keywords. Sources: CNBC, MarketWatch, Nasdaq, Investing.com, BBC Business, OilPrice.com (public RSS) and Yahoo Finance. Tags are automatic and can be wrong. MTD = month-to-date return of each model's current holdings (hypothetical, before costs).
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
SURVYR
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026